Our Blog

Mesoblast (ASX:MSB) reports a net loss US$45.3 million for nine months

28 May 2020 – Mesoblast (ASX:MSB), the company that develops cellular medicines for inflammatory diseases, has reported a net loss of $US45.3 million in the nine months to the end of March.


Source: Finance News Network

Share this post